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The 2015 Nobel Prize in Physiology or Medicine has been awarded to William C. Campbell, Satoshi
Omura, and Youyou Tu for the discovery of avermectins and artemisinin, respectively, therapies
that revolutionized the treatment of devastating parasite diseases. With the recent technological
advances, a New Golden Age of natural products drug discovery is dawning.Natural products possess enormous
structural and chemical diversity that
cannot be matched by any synthetic li-
braries of small molecules and continue
to inspire novel discoveries in chemistry,
biology, and medicine. They are evolu-
tionarily optimized as drug-like molecules
and remain the best sources of drugs and
drug leads (Newman and Cragg, 2012).
The history of medicine is full of remark-
able stories of how the discovery of a nat-
ural product profoundly impacted ad-
vances in biology and inspired drug
discovery and therapy. For instance, pac-
litaxel’s impact on tubulin polymerization
and correlation to antitumor action or ra-
pamycin’s binding to mTOR and the rami-
fication of mTOR inhibitors could never be
predicted a priori. The award of the Nobel
Prizes in Physiology or Medicine to Sir
Alexander Fleming, Ernst B. Chain, and
Sir Howard Florey in 1945 for the discov-
ery of penicillin and to Selman A. Waks-
man in 1952 for the discovery of strepto-
mycin heralded the start of a period from
1950s to 1960s known as the Golden
Age of natural product drug discovery.
Since the late 20th century, however,
many pharmaceutical companies have
significantly scaled back or abandoned
their natural product programs, in part
because of the phenomenal advances in
both high-throughput screening (HTS)
and combinatorial synthesis, thereby the
creation of enormous synthetic libraries
of small molecules. In contrast, natural
product libraries often consisted of ex-
tracts and partially purified fractions, inaddition to pure compounds, and were
perceived tobe incompatiblewith contem-
poraryHTSplatforms. Thisde-emphasis in
natural product drug discovery unfortu-
nately correlatedwith the overall reduction
in new leads in thedrugdevelopmentpipe-
line and the substantial decline in newdrug
approval (Li and Vederas, 2009).
The award of the 2015 Nobel Prize in
Physiology or Medicine to William C.
Campbell and Satoshi Omura, for the dis-
covery of the microbial natural product
avermectins, the derivatives ofwhich, iver-
mectin (Figure 1A), have radically lowered
the incidence of onchocerciasis (also
known as river blindness) and lymphatic
filariasis (also known as elephantiasis)
and to Youyou Tu for the discovery of the
plant natural product artemisinin
(Figure 1B), a drug that has significantly
reduced the mortality rates for patients
suffering from malaria, therefore brought
the greatest pride and optimism to the nat-
ural product community worldwide.
Together with the recent advances in mi-
crobial genomics andmetagenomics, syn-
thetic biology, fundamental understanding
of natural product biosynthesis, and bioin-
formatics and analytical technologies, we
are surely entering a New Golden Age of
natural products drug discovery.
‘‘Splendid Gifts from
Microorganisms’’
The discovery of the avermectins resulted
from an intensive search for microbial nat-
ural products with anthelmintic activities
and exemplified the best team effort fromCell 163, Dan academic and industry collaboration
led by Campbell, a parasitologist at the
Merck Research Laboratories, and
Omura, a microbial natural product
chemist at the Kitasato Institute. The
choiceof natural products as thepreferred
source for initial screening was deeply
rooted to Campbell’s belief that nature
constantly produces molecules that have
not been thought of by humans and to
Omura’s personal research philosophy of
exploiting the potential ofmicroorganisms
and microbial metabolites, ‘‘splendid
gifts’’ as he calls them, to advance scienti-
fic progress and to accelerate and maxi-
mize improvement in human health and
welfare worldwide (Omura, 2011).
In the early 1970s, Merck decided to
search for new anthelmintics from micro-
bial natural products. While microbial fer-
mentations had been extensively
screened for anticancer and antibacterial
agents, parasitologists at the time had
not tried this strategy, partly due to the
lack of suitable assays. At the same
time, the Kitasato Institute entered into a
research agreement with Merck to screen
for novel antibacterial agents from soil mi-
crobes isolated in Japan. This agreement
was subsequently amended such that
Kitasato Institute would send lyophilized
cultures of the most chemically or
morphologically ‘‘unusual’’ ones to Merck
for any additional assays.
Initial examination of microbial cultures
by several different in vitro assays was
disappointing, primarily because of the
large number of toxic compounds thatecember 3, 2015 ª2015 Elsevier Inc. 1297
Figure 1. Discovery of Avermectin from S. avermitilis and Artemisinin from A. annua
(A) Soil samples Omura collected near a golf course, fromwhich the avermectin-producing S. avermitiliswas isolated, and Campbell discovered avermectins and
developed them into ivermectin.
(B) The ancient Chinese medicine ‘‘Handbook of Prescriptions for Emergencies’’ that inspired Tu to discover artemisinin from the A. annua L. plants.had to be eliminated. This prompted
Merck to develop an in vivo assay in
mice with the hope that the mice would
screen out the non-specific toxic com-
pounds. Thus, mice infected with the
nematode Nematospiroide dubius were
fed a diet mixed with the fermentation
products to be tested and subsequently
examined for the absence of eggs in fecal
pellets and worms in small intestines. This
assay turned out to be very successful,
most importantly allowing the differentia-
tion of nonspecific toxic activities from
the true antiparasitic activity. Among the
many thousands of cultures tested was
one group of 54 cultures from the Kitasato
Institute, including the now famous
OS3153 strain isolated by Omura near a
golf course. As fate would have it,
OS3153 was almost missed in the initial
assay because of substantial toxicity,
but confirmatory tests firmly established
an extremely potent anthelmintic activity
at 0.0003% in diet.
OS3153 was identified as a novel spe-
cies, named Streptomyces avermitilis,
and the metabolites responsible for the
activity were named avermectins. Despite
decades of searching around the world,
the S. avermitilis strain discovered by
Omura remains the only avermectin-pro-
ducing organism ever found, underscor-
ing its rarity. The wild-type strain pro-1298 Cell 163, December 3, 2015 ª2015 Elseduced avermectins at a yield of 9 mg/l.
Subsequent strain improvement resulted
in 50-fold increase in avermectin yield by
the production strain.
The avermectins consisted of eight
closely related congeners, comparison
among which revealed insightful struc-
ture-activity relationship. 22,23-Dihy-
droavermectin B1, named ivermectin
(Figure 1A), was selected for development
based on its exceptional potency against
an unprecedented array of nematodes
and arthropod parasites and a preferable
safety profile. Its novel chemical struc-
ture, a 16-membered macrolide bearing
two unusual deoxysugars, and mode of
action, by hyperpolarizing neurons via
the binding to receptors of glutamate-
gated chloride ion channels, probably ac-
count for the lack of any cross-resistance
to known antiparasitic agents. Since be-
ing marketed in 1981, ivermectin has
become the most revolutionary parasiti-
cide in animal health.
Development of ivermectin as a human
medicine for onchocerciasis originated
with the early observations by Merck sci-
entists that ivermectin was very effective
against the skin-dwelling microfilariae of
Onchocerca cervicalis in horse. Since
O. cervicalis belongs to the same genus
as Onchocerca vulvulus, the causative
parasite for onchocerciasis in human,vier Inc.Campbell hypothesized that ivermectin
would be effective against onchocerci-
asis. It was indeed found to be highly
effective against the parasitic worms
responsible for onchocerciasis and sub-
sequently in combinatorial therapy for
lymphatic filariasis (Campbell et al.,
1983; Campbell 1993; Omura and Crump
2004, 2014). Today, under the brand
name of Mectizan and via an unprece-
dented drug donation program, iver-
mectin provided us with a revolutionary
therapy against onchocerciasis and
lymphatic filariasis, mass distribution of
which has become so successful that
river blindness and elephantiasis are on
the verge of eradication.
Deciphering the Ancient Chinese
Medicine Code
The discovery of artemisinin (qinghaosu ‘‘
青蒿素 ’’ in Chinese) came from an inten-
sive search for plant natural products
with antimalaria activity and represented
a nationwide collaborative effort during
the ‘‘Culture Revolution’’ period from the
1960s to 1970s in China. Tu, a phyto-
chemist and the head of the malaria
research group at the China Academy of
Chinese Medical Sciences, was destined
to make the Nobel Prize-winning discov-
ery of artemisinin due to her unique train-
ings in both Western and Chinese
medicines and her belief in the wisdom of
Chinese medicine and determination to
exploit ‘‘gifts from Chinese medicine’’ to
conquer life-threatening diseases world-
wide (Tu, 2011).
In the 1960s, malaria rebounded with a
vengeance, primarily due to resistance to
chloroquine, the antimalaria drug of
choice at the time. ‘‘Project 523,’’ initiated
on May 23, 1967, by the Chinese govern-
ment, enlisted more than 60 academic
and military institutions and more than
500 researchers, with the estimation of
an additional 2,000 to 3,000 people
involved at one time or another, to
discover a new antimalaria drug. Efforts
in the first 2 years included both screening
known compounds (40,000) for leads
and combing the traditional Chinesemed-
icine literatures for hints; however, they
were disappointing, yielding nothing of
practical values.
Tuwas asked to join the project in 1969.
Knowing the setbacks in the previous two
years, Tu and colleagues first surveyed
traditional Chinese medicine records and
literatures and visited many herbalists
and rural healers all over China. As a
result, they compiled a list of more than
200 traditional Chinesemedicine receipts,
consisting of more than 2,000 herbs, with
indications of treating fever, thereby
possible antimalaria activities. However,
initial evaluations of 380 extracts,
made from 200 selected herbs, were
simply disappointing, with malaria inhibi-
tion in a mouse model, infected with the
malaria parasite Plasmodium berghei,
straggling at 12%–14%.
The breakthrough came from an
extract, made from the plantArtemisia an-
nua L. (also known as qinghao or sweet
wormwood), that showed promising anti-
malaria activity in the mouse model, but
this activity was not reproducible. Upon
re-examining a book titled ‘‘Handbook of
Prescriptions for Emergencies’’ by Ge
Hong, a fourth-century healer, which
called for ‘‘soaking one bunch of qinghao
in two liters of water, squeezing and then
drinking the juice,’’ Tu reasoned that the
active ingredients may be not stable un-
der the traditional Chinesemedicine prep-
aration by boiling. Inspired by this pas-
sage, Tu made what is now known as
the most important decision leading to
the discovery of artemisinin to experiment
alternative methods of extraction at lowertemperatures. Finally, an extract made
with diethyl ether afforded a reproducible
antimalaria activity, from which artemisi-
nin was finally isolated and showed
100% efficacy against malaria in the ani-
mal models. Within the genus Artemisia,
we now know that A. annua is the only
species that contains artemisinin, most
of which is enriched in the leaves of plants
harvested in the later summer and early
fall. Artemisinin yields also vary from
0.01% to 0.5% with the plants growing
in Sichuan, China, in comparison to
0.06% with plants growing in the Wash-
ington, D.C., vicinity. The ancient code
was finally deciphered.
The ensuingevents leading to the clinical
development of artemisinin into an antima-
laria drug were by no means conventional
either. At the timewithmost of the scientific
establishments in China on standstill, Tu
and two colleagues bravely tested the
safety of the active compound, before
knowing its chemical structure, on their
own. Upon confirming that the compound
was safe, they completed the very first clin-
ical trials for 30 patients infected with both
Plasmodium vivax and Plasmodium fulci-
parum, all of which were successful. It
was only then that systematic character-
izations of the chemistry and pharma-
cology for the active compound started.
The structure of the active compound,
named artemisinin, was established. It
belongs to the amorphane family of ses-
quiterpenes but features a rare peroxy
bridge (Figure 1B). Artemisinin was highly
effective against the malaria parasites,
including those that were resistant to
chloroquine. It rapidly kills the malaria
parasites at an early stage of their devel-
opment, which explains its unprece-
dented potency in the treatment of severe
malaria. It was estimated that, during the
three year period between 1975 and
1978 alone, clinical trials on more than
6,550 patients were completed, all of
which were successful. Thus was born ar-
temisinin, a completely novel class of an-
timalarias. Analogues of artemisinin, such
as dihydroartemisinin, artemether, and ar-
tesunate, were subsequently found to be
more potent than artemisinin itself and
are now completely changing the land-
scape of antimalaria chemotherapies
(Klayman, 1985; Tu, 2011).
It is worth noting that the impact of arte-
misinin as a novel class of antimalariaCell 163, Ddrugs onworld health was not realized un-
til nearly 30 years after its effectiveness
was firmly established in China. WHO
started to adopt artemether as a front-
line antimalaria drug in 2001 and switched
to the artemisinin-based combination
therapies in 2005, which now are esti-
mated to reduce mortality from malaria
by more than 20% overall and by more
than 30% in children.
A New Golden Age of Natural
Products Drug Discovery
This year’s Nobel Prize-winning discov-
eries will surely inspire the world to
continue the search for history-changing
natural product drugs. There were many
parallels between the discovery and
development of avermectins and artemi-
sinin into paradigm-shifting medicines
that could enlighten the scientific commu-
nity to reconsider the perceived incom-
patibility of natural products with contem-
porary HTS platforms for drug discovery.
Both programs started with massive
screening campaigns against libraries of
known compounds and natural product
extracts of microbial or plant origins, but
the eventual breakthroughs both came
from natural products. The in vivo models
allowed differentiation between the true
biological activity from non-specific toxic-
ities, thereby allowing resources to be
devoted preferentially to the most prom-
ising leads. While it is inconceivable
today, in both cases, the efficacy of the
active compounds was firmly established
in multiple animal models before pursuing
chemical structure elucidation. For arte-
misinin, the initial trials on patients were
carried out with the preparation without
knowing its structure, though its safety
was established and this was done more
out of the historical circumstances rather
than by choice. After more than 30 years
of successful clinical application, the
exact modes of action for both ivermectin
and artemisinin remain poorly under-
stood. While the structural complexity
and rich functionalities have been
credited for their great potency and exqui-
site selectivity, natural products often
interact with multiple biological targets,
challenging the prevailing paradigm of
mechanism-based drug discovery. Inves-
tigations of the multitude modes of action
for natural product drugs, therefore,
promise to reveal the intricate interplayecember 3, 2015 ª2015 Elsevier Inc. 1299
of biology, thereby providing new oppor-
tunities for drug discovery. The unprece-
dented scaffolds of the natural products
have served as great inspiration for the
next generation of therapeutics, as exem-
plified by the many analogs, with designer
properties, derived from avermectins and
artemisinin. It is precisely the novel chem-
ical scaffolds of the avermectins and arte-
misinin that account for their lack of
cross-resistance to many of the known
drugs. This is particularly imperative for
antibiotics since resistance is inevitable.
The world would be better served when
these lessons are taken into consideration
in the quest for the next wave of wonder
drugs.
It has been more than 30 years since
the ivermectin and artemisinin families of
drugs were first introduced as human
therapies. Resistances to both drugs
have been observed and continue to
rise. The world has invested billions of
dollars to search for novel anthelmintic
and antimalaria drugs but without a
fundamental breakthrough. Is it a time to
reconsider natural products?
The genome of the avermectin-produc-
ing S. avermitilis strain has since been
sequenced, revealing, among the many
surprises, its potential to biosynthesize
at least 36 other natural products, in addi-
tion to avermectins, and the 80 kb aver-
mectin gene cluster, setting the stage to
improve avermectin production and engi-
neer avermectin analogs by manipulating
its biosynthesis (Ikeda et al., 1999).
Indeed, targeting genes encoding the
specific steps in avermectin biosynthesis
has already demonstrated the feasibility
to produce selected avermectin conge-
ners and improve overall yields. While de-
cades of search around the world have
yet to discover other avermectin pro-
ducers, gene clusters homologous to
avermectin biosynthesis have been
discovered, providing outstanding oppor-
tunities to engineer novel avermectin ana-
logs by exploring combinatorial biosyn-
thesis strategies.1300 Cell 163, December 3, 2015 ª2015 ElseReliable supplies of artemisinin based
on massive cultivation of A. annua, given
its low yield and regional and seasonal
variations, have always been a concern.
The artemisinin structure was unprece-
dented when it was first discovered nearly
40 years ago, but now,much of its biosyn-
thesis is known. In a remarkable triumph
of synthetic biology, artemisinic acid, the
key precursor from which artemisinin
and other artemisinin analogs can be
readily prepared by chemical synthesis,
can now be produced by fermentation of
a recombinant yeast carrying genes hi-
jacked from A. annua to convert farnesyl
diphosphate, the universal precursor for
sesquiterpenes, to artemisinic acid in a
whopping yield of 25 g/l (Paddon et al.,
2013).
We are surely entering a New Golden
Age of natural products drug discovery.
Recent advances in microbial genomics
and metagenomics have definitively re-
vealed that the vast majority of Earth’s
biodiversity is yet to be exploited for natu-
ral products discovery (Charlop-Powers
et al., 2014). Innovations in microbial culti-
vation (Ling et al., 2015) and synthetic
biology (Paddon et al., 2013) have radi-
cally expanded the chemical space of
natural products and demonstrated the
feasibility of engineered production of
natural products from uncultivated spe-
cies or species on the verge of extinction
in model heterologous hosts. Funda-
mental understandings of natural product
biosynthesis have allowed rational manip-
ulation of nature’s biosynthetic machinery
for the production of both the natural
products and their engineered variants.
Genome mining for nature’s myriad so-
called ‘‘cryptic’’ natural product biosyn-
thetic pathways has started to awaken
these ‘‘sleeping beauties.’’ Finally,
emerging strain prioritization, bioinfor-
matics, and analytical technologies have
revolutionized natural product dereplica-
tion, enabling structural prediction, rapid
detection, and isolation of themost prom-
ising natural products in a rapid pacevier Inc.(Bouslimani et al., 2014; Rudolf et al.,
2016). Nature has been extremely
generous in offering mankind live-saving
therapies, and the next great drug may
be just around the corner—are we ready
to seize the opportunity?ACKNOWLEDGMENTS
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